4-bromo A23187
(Synonyms: 4-溴代-钙离子载体,4-Bromocalcimycin) 目录号 : GC42346A non-fluorescent calcium ionophore
Cas No.:76455-48-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
4-bromo A23187 is a halogenated analog of the highly selective calcium ionophore A23187. 4-bromo A23187 is non-fluorescent.[1] As a result, it is often used in experiments where fluorescent probes are employed.[2],[3]
Reference:
[1]. Deber, C.M., Tom-Kun, J., Mack, E., et al. Bromo-A23187: A nonfluorescent calcium ionophore for use with fluorescent probes. Anal.Biochem. 146(2), 349-352 (1985).
[2]. Ducreux, S., Gregory, P., and Schwaller, B. Inverse regulation of the cytosolic Ca2+ buffer parvalbumin and mitochondrial volume in muscle cells via SIRT1/PGC-1α axis. PLoS One 7(9), (2012).
[3]. Yang, J., Singh, V., Cha, B., et al. NHERF2 protein mobility rate is determined by a unique C-terminal domain that is also necessary for its regulation of NHE3 protein in OK cells. J.Biol.Chem. 288(23), 16960-16974 (2013).
Cas No. | 76455-48-6 | SDF | |
别名 | 4-溴代-钙离子载体,4-Bromocalcimycin | ||
化学名 | 6-bromo-5-(methylamino)-2-[[(2R,3R,6S,8S,9R,11R)-3,9,11-trimethyl-8-[(1S)-1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl]-1,7-dioxaspiro[5.5]undec-2-yl]methyl]-4-benzoxazolecarboxylic acid | ||
Canonical SMILES | O=C(C1=C2N=C(C[C@H]3O[C@]4(O[C@H]([C@H](C)C(C5=CC=CN5)=O)[C@H](C)C[C@H]4C)CC[C@H]3C)OC2=CC(Br)=C1NC)O | ||
分子式 | C29H36BrN3O6 | 分子量 | 602.5 |
溶解度 | 1mg/mL in DMSO, 10mg/mL in DMF | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.6598 mL | 8.2988 mL | 16.5975 mL |
5 mM | 0.332 mL | 1.6598 mL | 3.3195 mL |
10 mM | 0.166 mL | 0.8299 mL | 1.6598 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Tamoxifen inhibits Ca2+ uptake by the cardiac sarcoplasmic reticulum
Pflugers Arch 2000 Aug;440(4):573-9.PMID:10958341DOI:10.1007/s004240000318.
Ca2+ transients in isolated cardiac ventricular myocytes and the amount of Ca2+ that could be released from the sarcoplasmic reticulum (SR) in these cells by caffeine were reduced in the presence of tamoxifen. To examine the effects of tamoxifen on the cardiac muscle SR directly, isolated SR vesicles and fluorimetry methods were used to measure the uptake of Ca2+ by the SR and the ATPase activity of the SR Ca2+ pump. SR Ca2+ uptake was inhibited by tamoxifen at concentrations greater than 2.4 microM. Half-maximal inhibition was seen at approximately 5 microM. Inhibition of uptake was not due to the development of a substantial tamoxifen-dependent leak of Ca2+ from the SR or to a direct inhibitory effect of tamoxifen on the ATPase activity of the SR Ca2+ pump. In addition to its effect on SR Ca2+ uptake, tamoxifen also reduced the rate at which stored Ca2+ could be released from the SR by the Ca2+ ionophore 4-bromo A23187. Our results are consistent with the hypothesis that tamoxifen inhibits an ion current that accompanies Ca2+ movement across the SR membrane. This possibility is also consistent with the known inhibitory action of tamoxifen on some types of Cl- and K+ channels.